申请人:Merck Sharp & Dohme Ltd.
公开号:US06127388A1
公开(公告)日:2000-10-03
A class of substituted azetidine, pyrrolidine and piperidine derivatives of Formula I are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D.alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D.alpha. receptor subtype relative to the 5-HT.sub.1D.beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists. ##STR1##
公式I中的一类取代的氮杂环化合物,包括氮杂环丙烷,吡咯烷和哌嗪衍生物,是5-HT.sub.1-类受体的选择性激动剂,是人类5-HT.sub.1D.alpha.受体亚型的有效激动剂,同时相对于5-HT.sub.1D.beta.亚型具有至少10倍的选择亲和力;因此,它们在治疗和/或预防临床情况方面是有用的,特别是偏头痛和相关疾病,需要5-HT.sub.1D受体亚型选择性激动剂,同时引起的副作用较少,特别是不良心血管事件,比与非亚型选择性5-HT.sub.1D受体激动剂相关的副作用更少。##STR1##